| Document |
Document Title |
|
WO/2020/040448A1 |
The present invention relates to a method for synthesis of TKX-50 using an insensitive intermediate and, more specifically, to a method for producing TKX-50, the method comprising the steps of: preparing DCG as a starting material; formi...
|
|
WO/2020/027304A1 |
Provided are carotenoid derivatives having exceptional hydrophilicity and oral absorptivity. A carotenoid-related compound represented by the formula (in the formula, X represents a carbonyl group or a methylene group, and Z1 and Z2 are ...
|
|
WO/2020/019994A1 |
Disclosed is a compound having a neuroprotective effect, a preparation method therefor and a use thereof. In particular, disclosed is a compound as shown in general formula A or a pharmaceutically acceptable salt thereof. Also disclosed ...
|
|
WO/2020/020851A1 |
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
|
|
WO/2020/020849A1 |
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
|
|
WO/2020/020850A1 |
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
|
|
WO/2020/012372A1 |
The present invention relates to an improved process for the preparation of 2,2',2''-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid, gadolinium (III) with iron metal content less than...
|
|
WO/2020/010643A1 |
A method for synthesizing valsartan, comprising the steps of: synthesizing a valsartan methyl ester intermediate to obtain a reaction mixture of the valsartan methyl ester intermediate; diluting the reaction mixture by salt water or wate...
|
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2019/243799A1 |
The present disclosure relates to a hybrid salt/co-crystal of sacubitril. The present disclosure is also related to processes for the preparation of the hybrid salt/co-crystal of sacubitril. In addition, the present disclosure is related...
|
|
WO/2019/243358A1 |
The present invention relates to compounds Formula (I): wherein Q, R2, R3, R4 and R5 are as defined herein. The invention further relates to compositions comprising said compounds, and methods of controlling weeds using said compounds an...
|
|
WO/2019/246445A1 |
The present invention provides a compound having the structure: and methods of using the compound in targeted PET imaging.
|
|
WO/2019/241594A1 |
Provided herein are DOTA-containing compounds (e.g., compounds of Formula (I)) and complexes that are reactive with an enzyme activator (e.g., a peroxidase) and covalently bind a target analyte (e.g., a protein) in a catalyzed reporter d...
|
|
WO/2019/239432A1 |
The present invention relate to trisodium sacubitril valsartan complex with polymer as an extrudate and to a hot melt extruded pharmaceutical composition comprising, trisodium salt of valsartan sacubitril and at least one pharmaceuticall...
|
|
WO/2019/236988A1 |
Provided herein are methods, reagents, and kits for isolating polypeptides, such as a proteome. Also provided herein is a modified trypsin polypeptide that is resistant to autolysis, and that can be selectively-separated from a biologica...
|
|
WO/2019/232724A1 |
The present invention relates compounds of Formula (I) - (V), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as nuclear transport modulators. The present i...
|
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
|
WO/2019/212356A1 |
Disclosed herein are tetrazines substituted with groups that result in a high click conjugation yield in vivo and high click release yields. In one aspect, the invention relates to kits comprising said tetrazines and a dienophile, prefer...
|
|
WO/2019/213579A1 |
Disclosed herein are compounds having antiviral activity, and, in particular, an inhibitory activity on the replication of Respiratory Syncytial Virus (RSV). Druggable target sites, including Px, in the RSV N protein are disclosed, as we...
|
|
WO/2019/206695A1 |
The invention relates to a process for the preparation of 1-(2-methoxymethyl-3- methylphenyl)4H-tetrazolin-5-one, comprising a step of reacting an isocyanate compound with an azide salt in a solvent and in the presence of a silicon deriv...
|
|
WO/2019/206696A1 |
The invention relates to a process for the preparation of a tetrazolinone compound, comprising a step of reacting an isocyanate compound with an azide salt in a solvent and in the presence of a silicon derivative as a catalyst.
|
|
WO/2019/203191A1 |
The present invention relates to a labeling technique with which, without deterioration in the function of an antibody, metabolization in the liver after administration to a patient is facilitated and accumulation of radionuclides in org...
|
|
WO/2019/191502A1 |
This disclosure concerns compounds and a method for modulating the activity of calcium ion channels, including Ca2+-induced (or Ca2+-activated) calcium release channels and conformationally coupled calcium release channels such as ryanod...
|
|
WO/2019/183587A1 |
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurolo...
|
|
WO/2019/182395A1 |
In the compound of the present invention and in an anti-inflammatory agent, a cyclooxygenase-2 inhibitor, a therapeutic agent for brain diseases, and an MRI contrast medium, which each comprise the same compound, the compound of the pres...
|
|
WO/2019/183373A1 |
Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and metho...
|
|
WO/2019/182393A1 |
In a compound having a novel structure, an anti-inflammatory agent comprising same, and a matrix metalloprotease-9 inhibitor comprising same of the present invention, the compound of the present invention has the structure represented by...
|
|
WO/2019/180735A1 |
The present invention relates to pharmaceutical compositions comprising sacubitril-valsartan complex. More particularly, the present invention relates to a stable composition comprising trisodium salt of sacubitril-valsartan complex trih...
|
|
WO/2019/162313A1 |
The invention relates to a process for producing a contrast agent-containing pharmaceutical preparation, which contains as the contrast agent a complex of a lanthanide, in particular gadolinium, and a macrocyclic chelate, in particular D...
|
|
WO/2019/162309A1 |
The present invention relates to benzamide compounds of formula I (I) wherein the variables are defined as in the claims and the description, the N-oxides and salts thereof,and to compositions comprising the same. The invention also rela...
|
|
WO/2019/157037A1 |
Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule ra...
|
|
WO/2019/154974A1 |
The present invention discloses thermally stable free thiophene croconaine dyes of formula (I), where R1-R4 are 1-20C alkyl or alkenyl groups, and their even more thermally stable complexes with anthracenyl-tetralactam macro molecules, w...
|
|
WO/2019/147912A1 |
The present invention is directed to radiopharmaceuticals with improved stability, a kit, and a method of production thereof.
|
|
WO/2019/143074A1 |
Disclosed is a method for producing calcobutrol used as an MRI contrast agent. The method for producing calcobutrol comprises the steps of: obtaining butrol represented by chemical formula 2 in the specification by reacting gadobutrol re...
|
|
WO/2019/141740A1 |
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, X, Z, R2 and R3 are as described herein. The inventions further relates to compositions comprising said compounds, to meth...
|
|
WO/2019/143073A1 |
Disclosed are an intermediate for gadoteridol used as an MRI contrast agent, and a method for preparing gadoteridol using same. Provided, as a gadoteridol intermediate, is 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane, which is rep...
|
|
WO/2019/142192A1 |
Novel compounds capable of inhibiting methionine metabolic pathway are provided. These compounds are used in inhibiting cystathionin γ-synthase (CGS) in general, and in plants, fungi and bacteria, in particular. These compounds of the i...
|
|
WO/2019/138323A1 |
This invention relates to compounds of formula 1, 2 or 3, Formulae (1), (2), (3), a pharmaceutically acceptable salt, or a solvate thereof, wherein X1, Y, R1, R2, R3, R4, and R5 are as defined herein. The compounds are antimicrobial agen...
|
|
WO/2019/134993A1 |
The present invention relates to benzamide compounds of formula (I), the N-oxides and the salts thereof (I), where the variables are as defined in the claims and the description. The invention also relates to compositions comprising such...
|
|
WO/2019/134765A1 |
The invention concerns a sartan analogue on basis of a sartan which sartan comprises an alkyl group or an alkoxy group, wherein the sartan analogue only differs from the sartan by a replacement of the alkyl group or the alkoxy group or r...
|
|
WO/2019/127994A1 |
The present invention relates to a sacubitril sodium salt as represented by formula IV, a eutectic of sacubitril free acid and acetic acid, a crystal form of the eutectic and a preparation method for the crystal form, and a method for us...
|
|
WO/2019/132782A1 |
A compound of formula (I) or a salt, solvate or prodrug thereof: wherein R1 and R4 are independently selected from C1-C5 alkyl, C1-C5 haloalkyl, C1-C5 alkenyl, C1-C5 haloalkenyl, C1-C5 alkynyl, C1-C5 haloalkynyl, C1-C5 alkoxy or C1-C5 ha...
|
|
WO/2019/122345A1 |
The present invention relates to benzamide compounds of formula I wherein the variables are defined as in the claims and the description, the N-oxides and salts thereof,and to compositions comprising the same. The invention also relates ...
|
|
WO/2019/105995A1 |
The present invention relates to benzamide compounds of formula (I), their N-oxides and salts thereof and to compositions comprising the same. The invention also relates to the use of the benzamide compounds or of the compositions compri...
|
|
WO/2019/106182A1 |
The present invention relates to compounds of general formula (I) for chromatographic separation of rare earth elements and/or s-, p-, d- metals, as well as to the method of the separation of rare earth elements.
|
|
WO/2019/101729A1 |
The present invention relates to a compound or a pharmaceutically acceptable salt thereof of formula (I) wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of ra...
|
|
WO/2019/096884A1 |
The invention relates to benzoyl amides of general formula (I), as herbicides. In formula (I), B is N or CH, and X1 and X2 are O or S(O)n. R, Ra and Rb are groups such as hydrogen, halogen, (C1-C6)-alkyl, halogen-(C1-C6)-alkyl, (C1-C6)-a...
|
|
WO/2019/091389A1 |
Fluorescent probes for silver ion detection include organic, water-soluble compounds having aggregation-induced emission (AIE) characteristics. The probes can sense or detect silver ions through aggregation or a precipitation reaction be...
|
|
WO/2019/092086A1 |
The present invention relates to tetrazolylpropyl derivatives of formula (I) wherein one of V1 and V2 represents CR3 and the other one of V1 and V2 represents N, Q represents a 6- membered aromatic cycle as defined in the specification, ...
|
|
WO/2019/079485A1 |
The present disclosure relates to amine-substituted heterocyclic compounds and derivatives thereof. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., c...
|
